Loading
A phase 2 trial of Zimberelimab, Domvanalimab, Sacituzumab govitecan in non-small-cell lung cancer and small-cell lung cancer, run by Gilead Sciences, active and no longer recruiting.
Study of Novel Treatment Combinations in Patients With Lung Cancer is a phase 2 interventional study registered as NCT05633667 by Gilead Sciences, with 192 participants enrolled, started 2023-03-16 and due to reach its primary completion in 2029-09. Interventions recorded: Zimberelimab (ZIM), Domvanalimab (DOM), Sacituzumab govitecan-hziy (SG), Etrumadenant (ETRUMA), Carboplatin. Conditions listed: Lung Cancer, Advanced or Metastatic Non-Small-Cell Lung Cancer, Resectable Non-Small-Cell Lung Cancer. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Domvanalimab, Zimberelimab, Gilead Sciences (incl. Kite), Small-cell lung cancer.
Shares Domvanalimab, Zimberelimab, Pemetrexed, Carboplatin.
Shares Domvanalimab, Zimberelimab, Gilead Sciences (incl. Kite), Carboplatin.
Shares Zimberelimab, Gilead Sciences (incl. Kite), Sacituzumab govitecan, Cisplatin.
Shares Domvanalimab, Gilead Sciences (incl. Kite), Non-small-cell lung cancer.
Shares Gilead Sciences (incl. Kite), Sacituzumab govitecan, Cisplatin, Carboplatin.
Shares Pemetrexed, Carboplatin, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Pemetrexed, Cisplatin, Carboplatin, Small-cell lung cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/